Literature DB >> 23944648

High doses of vascular endothelial growth factor 165 safely, but transiently, improve myocardial perfusion in no-option ischemic disease.

Imarilde I Giusti1, Clarissa G Rodrigues, Felipe B Salles, Roberto T Sant'Anna, Bruna Eibel, Sang W Han, Eduardo Ludwig, Gabriel Grossman, Paulo Roberto L Prates, João Ricardo M Sant'Anna, Guaracy F Teixeira Filho, Melissa M Markoski, Ivo A Nesralla, Nance B Nardi, Renato A K Kalil.   

Abstract

UNLABELLED: Gene therapy can induce angiogenesis in ischemic tissues. The aim of this study was to assess safety, feasibility, and results, both clinical and on myocardial perfusion, of gene therapy in refractory angina. This was a phase I/II, prospective, temporal-controlled series, clinical trial. Thirteen patients were maintained for minimum 6 months under optimized clinical management, and then received intramyocardial injections of 2000 μg plasmid vascular endothelial growth factor 165 and were followed by single-photon emission computed tomography (SPECT), treadmill tests, Minnesota quality of life questionnaire (QOL), and New York Heart Association (NYHA) functional plus Canadian Cardiovascular Society (CCS) angina classifications. There were no deaths, early or late. During the optimized clinical treatment, we observed worsening of rest ischemia scores on SPECT (p<0.05). After treatment, there was a transitory increase in myocardial perfusion at the third-month SPECT under stress (pre-operative [pre-op] 18.38 ± 7.51 vs. 3 months 15.31 ± 7.30; p<0.01) and at the sixth month under rest (pre-op 13.23 ± 7.98 vs. 6 months: 16.92 ± 7.27; p<0.01). One year after, there were improvements in treadmill test steps (pre-op 2.46 ± 2.07 vs.12 months 4.15 ± 2.23; p<0.01) and oxygen consumption (pre-op 7.66 ± 4.47 vs.12 months 10.89 ± 4.65; p<0.05), QOL (pre-op 48.23 ± 18.35 vs.12 months 28.31 ± 18.14; p<0.01) scores, and CCS (pre-op 3 [3-3.5] vs.12 months 2 [1-2.5]; p<0.01) and NYHA (pre-op 3 [3-3] vs. 2 [2-2] vs. 12 months 2 [1-2]; p<0.01) classes. Gene therapy demonstrated to be feasible and safe in this advanced ischemic cardiomyopathy patient sample. There were improvements in clinical evaluation parameters, and a transitory increase in myocardial perfusion detectable by SPECT scintigraphy. CLINICAL TRIAL REGISTRATION: NCT00744315 http://clinicaltrials.gov/

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23944648     DOI: 10.1089/hgtb.2012.221

Source DB:  PubMed          Journal:  Hum Gene Ther Methods        ISSN: 1946-6536            Impact factor:   2.396


  8 in total

Review 1.  Gene therapy for refractory angina and cell therapy for heart failure: experience of a Brazilian research group.

Authors:  Roberto Tofani Sant'Anna; Bruna Eibel; Melissa Medeiros Markoski; Clarissa Garcia Rodrigues; Felipe Borsu de Salles; Imarilde Inês Giusti; Ivo Abrahão Nesralla; Nance Beyer Nardi; Renato Abdala Karam Kalil
Journal:  Gene Ther       Date:  2019-07-05       Impact factor: 5.250

Review 2.  Gene delivery nanoparticles to modulate angiogenesis.

Authors:  Jayoung Kim; Adam C Mirando; Aleksander S Popel; Jordan J Green
Journal:  Adv Drug Deliv Rev       Date:  2016-11-30       Impact factor: 15.470

3.  Characteristics and Outcomes of Clinical Trials on Gene Therapy in Noncongenital Cardiovascular Diseases: Cross-sectional Study of Three Clinical Trial Registries.

Authors:  Witold Pinczak; Sylwia Trzcińska; Mikołaj Kamiński
Journal:  JMIR Form Res       Date:  2022-04-21

4.  Human Umbilical Cord-Derived Mesenchymal Stromal Cells Improve Left Ventricular Function, Perfusion, and Remodeling in a Porcine Model of Chronic Myocardial Ischemia.

Authors:  Chuan-Bin Liu; He Huang; Ping Sun; Shi-Ze Ma; An-Heng Liu; Jian Xue; Jin-Hui Fu; Yu-Qian Liang; Bing Liu; Dong-Ying Wu; Shuang-Hong Lü; Xiao-Zhong Zhang
Journal:  Stem Cells Transl Med       Date:  2016-06-22       Impact factor: 6.940

Review 5.  A snapshot of gene therapy in Latin America.

Authors:  Rafael Linden; Ursula Matte
Journal:  Genet Mol Biol       Date:  2014-03       Impact factor: 1.771

Review 6.  Advanced Strategies for End-Stage Heart Failure: Combining Regenerative Approaches with LVAD, a New Horizon?

Authors:  Cheyenne C S Tseng; Faiz Z Ramjankhan; Nicolaas de Jonge; Steven A J Chamuleau
Journal:  Front Surg       Date:  2015-04-07

7.  Long-term Intake of Pasta Containing Barley (1-3)Beta-D-Glucan Increases Neovascularization-mediated Cardioprotection through Endothelial Upregulation of Vascular Endothelial Growth Factor and Parkin.

Authors:  Valentina Casieri; Marco Matteucci; Claudia Cavallini; Milena Torti; Michele Torelli; Vincenzo Lionetti
Journal:  Sci Rep       Date:  2017-10-18       Impact factor: 4.379

Review 8.  Cell Therapy in Ischemic Heart Disease: Interventions That Modulate Cardiac Regeneration.

Authors:  Maximiliano I Schaun; Bruna Eibel; Melissa Kristocheck; Grasiele Sausen; Luana Machado; Andreia Koche; Melissa M Markoski
Journal:  Stem Cells Int       Date:  2016-01-05       Impact factor: 5.443

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.